PF-08046054

• Description :

  PF-08046054 (SGN-PDL1V) is a PD-L1-directed antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to the vedotin drug-linker, VcMMAE (HY-15575) . PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors[1].

• Product Name Alternative :

  SGN-PDL1V

• UNSPSC :

  12352203

• Target :

  Antibody-Drug Conjugates (ADCs) ; Microtubule/Tubulin; PD-1/PD-L1

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton; Immunology/Inflammation

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Purity :

  97.41

• Smiles :

  [PF-08046054]

• Molecular Weight :

  150166 (average)

• References & Citations :

  [1]Byron Kwan, et al. 783 SGN-PDL1V, a novel, investigational PD-L1-directed antibody-drug conjugate for the treatment of solid tumors Free. Regular and Young Investigator Award Abstracts. Immuno-Conjugates and Chimeric Molecules.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  -80°C, protect from light

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported